Nurzat Yeltai, Guo Zhenhe, Hu Julong, Lin Zaihuan, Zhang Qi, Liang Gang, Ji Hang, Zhang Xiaowen
From the State Key Laboratory of Respiratory Disease, Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Department of Plastic Surgery, Southern Medical University Third Hospital, Guangzhou, Yuexiu, People's Republic of China.
Plast Reconstr Surg Glob Open. 2025 Aug 18;13(8):e7028. doi: 10.1097/GOX.0000000000007028. eCollection 2025 Aug.
Keloids, benign skin tumors due to connective tissue overgrowth, can be exacerbated by ubiquitin-proteasome system abnormalities through uncontrolled inflammation. This study aimed to use Mendelian randomization (MR) analysis to explore keloid pathogenesis and identify target drugs for treatment.
The single-nucleotide polymorphism identifiers of keloid were obtained from the Open Genome-Wide Association Study database, and ubiquitin-related genes from GeneCards database. Five techniques were used for MR analysis during the research, with the accuracy of MR results evaluated by sensitivity analysis. Then, the R software package coloc was used for colocalization analysis of ubiquitin-related genes and keloid. Subsequently, the Comparative Toxicogenomics Database was used to predict skin complications related to keloid-associated target genes. Also, the Drug-Gene Interaction Database was used to study potential target drugs for target genes, and the mechanism of drug inhibition of keloid formation was explored using the DrugBank, Therapeutic Target Database, and STRING databases.
IFNGR1 and RNF187 were significant risk factors for keloid formation. A causal relationship exists between IFNGR1 and chronic skin ulcers (a keloid complication). Moreover, indole-3-carbinol, interferon gamma-1b, and pretomanid (targeting IFNGR1) are potential keloid treatments. Tretinoin can affect the IFNGR1 protein via the AKT1 pathway, inhibiting keloid proliferation.
IFNGR1 was associated with the pathogenesis of keloids. Interferon gamma-1b targeting IFNGR1 might be a potential strategy for the treatment of keloids, and this discovery opened up a new direction for the treatment of keloids.
瘢痕疙瘩是由于结缔组织过度生长引起的良性皮肤肿瘤,泛素 - 蛋白酶体系统异常通过不受控制的炎症可使其加重。本研究旨在使用孟德尔随机化(MR)分析来探索瘢痕疙瘩的发病机制并确定治疗靶点药物。
从开放基因组关联研究数据库中获取瘢痕疙瘩的单核苷酸多态性标识符,并从基因卡片数据库中获取泛素相关基因。研究过程中使用了五种技术进行MR分析,并通过敏感性分析评估MR结果的准确性。然后,使用R软件包coloc对泛素相关基因和瘢痕疙瘩进行共定位分析。随后,利用比较毒理基因组学数据库预测与瘢痕疙瘩相关靶基因的皮肤并发症。此外,使用药物 - 基因相互作用数据库研究靶基因的潜在靶向药物,并利用药物银行、治疗靶点数据库和STRING数据库探索药物抑制瘢痕疙瘩形成的机制。
IFNGR1和RNF187是瘢痕疙瘩形成的显著危险因素。IFNGR1与慢性皮肤溃疡(一种瘢痕疙瘩并发症)之间存在因果关系。此外,吲哚 - 3 - 甲醇、干扰素γ - 1b和pretomanid(靶向IFNGR1)是潜在的瘢痕疙瘩治疗药物。维甲酸可通过AKT1途径影响IFNGR1蛋白,抑制瘢痕疙瘩增殖。
IFNGR1与瘢痕疙瘩的发病机制相关。靶向IFNGR1的干扰素γ - 1b可能是治疗瘢痕疙瘩 的一种潜在策略,这一发现为瘢痕疙瘩的治疗开辟了新方向。